{"id":"placebo-acute-phase","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo is an inert substance administered in blinded clinical trials to establish baseline efficacy and safety profiles against which active investigational drugs are compared. In this Phase 3 acute phase trial context, placebo allows researchers to distinguish true drug effects from natural disease progression, spontaneous remission, and placebo response effects.","oneSentence":"Placebo produces no pharmacological effect and serves as a control comparator in clinical trials.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:26:33.320Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT05754957","phase":"PHASE3","title":"A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2023-04-07","conditions":"Acute Coronary Syndrome","enrollment":14194},{"nctId":"NCT06954987","phase":"PHASE2","title":"Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-07-17","conditions":"Acute Myeloid Leukemia","enrollment":244},{"nctId":"NCT07046494","phase":"PHASE2","title":"Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Bipolar I Disorder","status":"RECRUITING","sponsor":"Rapport Therapeutics Inc.","startDate":"2025-07-25","conditions":"Bipolar 1 Disorder","enrollment":224},{"nctId":"NCT04628026","phase":"PHASE3","title":"Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2","status":"RECRUITING","sponsor":"University of Ulm","startDate":"2022-09-13","conditions":"Acute Myeloid Leukemia","enrollment":650},{"nctId":"NCT04599478","phase":"PHASE2, PHASE3","title":"Pharmacological and Behavioral Treatment After Bariatric Surgery: Acute (Stage 1)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yale University","startDate":"2021-06-29","conditions":"Loss-of-control Eating, Obesity/Overweight","enrollment":160},{"nctId":"NCT06703073","phase":"PHASE2","title":"JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record)","status":"RECRUITING","sponsor":"PPD Development, LP","startDate":"2025-06-10","conditions":"Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome)","enrollment":600},{"nctId":"NCT07492771","phase":"PHASE1","title":"MP101 in Adults With Acute Pseudomonas Aeruginosa Pneumonia","status":"NOT_YET_RECRUITING","sponsor":"MicrobiotiX Co., Ltd","startDate":"2026-03","conditions":"Pneumonia - Bacterial, Pseudomonas Aeruginosa Infection","enrollment":18},{"nctId":"NCT06788756","phase":"PHASE2, PHASE3","title":"L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML","status":"RECRUITING","sponsor":"Moleculin Biotech, Inc.","startDate":"2025-03-12","conditions":"Acute Myeloid Leukaemia (AML)","enrollment":312},{"nctId":"NCT06701656","phase":"PHASE2","title":"JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort C: Bevacizumab","status":"RECRUITING","sponsor":"PPD Development, LP","startDate":"2025-10-28","conditions":"Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome)","enrollment":200},{"nctId":"NCT07492875","phase":"PHASE3","title":"Study of Nogapendekin Alfa Inbakicept and iNKT Cells in Critically Ill Adults With Severe Community-Acquired Pneumonia","status":"NOT_YET_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2026-04-15","conditions":"Community-Acquired Pneumonia (CAP), Acute Respiratory Distress Syndrome (ARDS), Sepsis","enrollment":10},{"nctId":"NCT07211958","phase":"PHASE3","title":"Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation","status":"RECRUITING","sponsor":"Syndax Pharmaceuticals","startDate":"2025-11-25","conditions":"Acute Myeloid Leukemias","enrollment":468},{"nctId":"NCT06701682","phase":"PHASE2","title":"JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort A: Vilobelimab","status":"RECRUITING","sponsor":"PPD Development, LP","startDate":"2025-06-21","conditions":"Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome)","enrollment":200},{"nctId":"NCT06701669","phase":"PHASE2","title":"JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort B: Paridiprubart","status":"RECRUITING","sponsor":"PPD Development, LP","startDate":"2025-06-10","conditions":"Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome)","enrollment":200},{"nctId":"NCT07216872","phase":"NA","title":"Safety and Effectiveness of the BrainsWay Deep Transcranial Magnetic Stimulation (Deep TMS) for Treatment of Alcohol Use Disorder (AUD)","status":"RECRUITING","sponsor":"Brainsway","startDate":"2025-11-07","conditions":"Alcohol Use Disorder, Alcoholism, Alcohol Abuse","enrollment":186},{"nctId":"NCT04107727","phase":"PHASE2","title":"Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML)","status":"COMPLETED","sponsor":"PETHEMA Foundation","startDate":"2019-09-05","conditions":"Acute Myeloid Leukemia","enrollment":273},{"nctId":"NCT07314060","phase":"PHASE2","title":"A Clinical Trial of TQH2929 Injection in Patients With Acute Flare-up of Generalized Pustular Psoriasis","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2026-03-19","conditions":"Generalized Pustular Psoriasis","enrollment":36},{"nctId":"NCT05065216","phase":"PHASE2, PHASE3","title":"Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)","status":"RECRUITING","sponsor":"DiaMedica Therapeutics Inc","startDate":"2021-11-07","conditions":"Acute Stroke, Ischemic Stroke, Stroke","enrollment":728},{"nctId":"NCT05992935","phase":"PHASE1, PHASE2","title":"Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age","status":"RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2023-08-25","conditions":"Norovirus Acute Gastroenteritis","enrollment":1405},{"nctId":"NCT05996835","phase":"PHASE2","title":"Phase 2b Study to Investigate the Safety and Efficacy of TIN816 in Sepsis-associated Acute Kidney Injury (CLEAR-AKI)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-01-18","conditions":"Acute Kidney Injury Due to Sepsis","enrollment":320},{"nctId":"NCT06641466","phase":"PHASE3","title":"A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-03-11","conditions":"Menstrual Migraine","enrollment":723},{"nctId":"NCT05488340","phase":"PHASE2","title":"A Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli (ELIMINATE Trial)","status":"RECRUITING","sponsor":"Locus Biosciences","startDate":"2022-07-13","conditions":"Urinary Tract Infections","enrollment":318},{"nctId":"NCT07355218","phase":"PHASE3","title":"A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)","status":"NOT_YET_RECRUITING","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2026-03-27","conditions":"Systematic Lupus Erythematosus, Cutaneous Lupus Erythematosus","enrollment":202},{"nctId":"NCT04649021","phase":"PHASE2","title":"Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b2) in Chinese Healthy Population","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2020-12-04","conditions":"SARS-CoV-2","enrollment":960},{"nctId":"NCT04649242","phase":"PHASE3","title":"Randomized Study in Children and Adolescents With Migraine: Acute Treatment","status":"RECRUITING","sponsor":"Pfizer","startDate":"2021-01-15","conditions":"Pediatric Migraine","enrollment":2100},{"nctId":"NCT07332481","phase":"PHASE3","title":"A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease","status":"NOT_YET_RECRUITING","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2026-03-27","conditions":"Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE)","enrollment":202},{"nctId":"NCT06852222","phase":"PHASE3","title":"A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2025-06-04","conditions":"Leukemia, Myeloid, Acute","enrollment":600},{"nctId":"NCT06226805","phase":"PHASE2","title":"Study of BB-031 in Acute Ischemic Stroke Patients (RAISE)","status":"RECRUITING","sponsor":"Basking Biosciences, Inc.","startDate":"2024-07-31","conditions":"Acute Ischemic Stroke","enrollment":228},{"nctId":"NCT05746559","phase":"PHASE3","title":"ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2023-04-06","conditions":"Chronic Kidney Disease, CKD, Cardiac Disease","enrollment":736},{"nctId":"NCT07214571","phase":"PHASE2","title":"A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of Progression to Severe Disease","status":"RECRUITING","sponsor":"Shionogi","startDate":"2025-12-11","conditions":"Respiratory Syncytial Virus Infections","enrollment":192},{"nctId":"NCT06699849","phase":"PHASE2","title":"Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis","status":"RECRUITING","sponsor":"CSL Behring","startDate":"2025-07-10","conditions":"Sickle Cell Disease Vaso-occlusive Crisis","enrollment":70},{"nctId":"NCT05396105","phase":"PHASE2, PHASE3","title":"Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema","status":"ENROLLING_BY_INVITATION","sponsor":"Pharvaris Netherlands B.V.","startDate":"2022-12-28","conditions":"Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II","enrollment":150},{"nctId":"NCT07473544","phase":"NA","title":"Essential Oil Inhalation and Acute Stress Response in Healthy Adults","status":"NOT_YET_RECRUITING","sponsor":"dōTERRA International","startDate":"2026-03-10","conditions":"Psychological Stress","enrollment":200},{"nctId":"NCT06602453","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of GDC-8264 in Preventing Cardiac Surgery-Associated Acute Kidney Injury (AKI) and Major Adverse Kidney Events (MAKE)","status":"TERMINATED","sponsor":"Genentech, Inc.","startDate":"2025-01-17","conditions":"Acute Kidney Injury","enrollment":67},{"nctId":"NCT06990867","phase":"PHASE2, PHASE3","title":"Optimizing Reperfusion to Improve Outcomes and Neurologic Function","status":"RECRUITING","sponsor":"Corxel Pharmaceuticals","startDate":"2025-05-15","conditions":"Acute Ischemic Stroke","enrollment":740},{"nctId":"NCT07007312","phase":"PHASE3","title":"Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML","status":"RECRUITING","sponsor":"Kura Oncology, Inc.","startDate":"2025-09-26","conditions":"Acute Myeloid Leukemia (AML)","enrollment":1300},{"nctId":"NCT05138822","phase":"PHASE1","title":"Safety, Tolerability, Pharmacokinetic and Microbiological Investigation of GSK3882347 in Female Participants With Urinary Tract Infections","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-05-18","conditions":"Uncomplicated Urinary Tract Infections, Urinary Tract Infections","enrollment":140},{"nctId":"NCT07221578","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder","status":"RECRUITING","sponsor":"Vanda Pharmaceuticals","startDate":"2025-09-22","conditions":"Social Anxiety Disorder (SAD)","enrollment":500},{"nctId":"NCT05702034","phase":"PHASE3","title":"A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2023-02-15","conditions":"Ischemic Stroke; Ischemic Attack, Transient","enrollment":15000},{"nctId":"NCT06193408","phase":"PHASE2","title":"Assessment of a Novel Fixed-dose Combination (FDC) Drug VR-AD-1005 for the Treatment of Acute Watery Diarrhea in Cholera","status":"COMPLETED","sponsor":"Hunazine Biotech S.L.","startDate":"2024-02-11","conditions":"Cholera","enrollment":150},{"nctId":"NCT07006636","phase":"NA","title":"Effect of Watermelon on Cardiometabolic Health","status":"NOT_YET_RECRUITING","sponsor":"University of California, Los Angeles","startDate":"2026-04-01","conditions":"Cardiometabolic Health Indicators, Whole-body Antioxidant Capacity","enrollment":22},{"nctId":"NCT00877903","phase":"PHASE2","title":"Prochymal® (Human Adult Stem Cells) Intravenous Infusion Following Acute Myocardial Infarction (AMI)","status":"COMPLETED","sponsor":"Mesoblast, Inc.","startDate":"2009-03-30","conditions":"Myocardial Infarction","enrollment":220},{"nctId":"NCT07463378","phase":"PHASE1","title":"Study of LUT017 Gel to Improve Healing of Skin Wounds After Removal of Benign Lesions in Healthy Adults","status":"NOT_YET_RECRUITING","sponsor":"Antoni Ribas","startDate":"2026-04","conditions":"Wound Healing, Acute Skin Wounds","enrollment":9},{"nctId":"NCT05658575","phase":"PHASE2, PHASE3","title":"Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare","status":"RECRUITING","sponsor":"Olatec Therapeutics LLC","startDate":"2023-01-06","conditions":"Acute Gout Flare, Gout Attack, Gout Flare","enrollment":300},{"nctId":"NCT04862221","phase":"PHASE2","title":"TReatment for ImmUne Mediated PathopHysiology","status":"RECRUITING","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2022-02-09","conditions":"Acute Liver Failure, Fulminant Hepatic Failure, Hepatic Encephalopathy","enrollment":163},{"nctId":"NCT06707493","phase":"PHASE2","title":"Ivosidenib as Post-HSCT Maintenance for AML","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2026-01-16","conditions":"IDH1 Mutation, Acute Myeloid Leukemia (AML), Hematopoietic Stem Cell Transplant (HSCT)","enrollment":75},{"nctId":"NCT07215702","phase":"PHASE2","title":"A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury.","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2026-02-10","conditions":"Sepsis, Acute Kidney Injury","enrollment":124},{"nctId":"NCT07453004","phase":"PHASE2","title":"A Study to Evaluate the Efficacy,Safety,Tolerability,Pharmacokinetics,and Immunogenicty of Plonmarlimab in Subjects With Acute Gouty Arthritis","status":"NOT_YET_RECRUITING","sponsor":"TJ Biopharma Co., Ltd.","startDate":"2026-04-01","conditions":"Acute Gouty Arthritis","enrollment":170},{"nctId":"NCT07449572","phase":"PHASE1","title":"Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HT31-1 for Treating ARDS","status":"NOT_YET_RECRUITING","sponsor":"HTIC, Inc","startDate":"2026-03","conditions":"ARDS (Acute Respiratory Distress Syndrome)","enrollment":24},{"nctId":"NCT05125302","phase":"PHASE3","title":"Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)","status":"RECRUITING","sponsor":"AbbVie","startDate":"2022-01-13","conditions":"Migraine","enrollment":1059},{"nctId":"NCT07308392","phase":"PHASE2","title":"Phase II Clinical Trial Evaluating the Efficacy and Safety of HRS-7249 and SHR-1918 in Patients With Severe Hypertriglyceridemia at High Risk of Acute Pancreatitis","status":"RECRUITING","sponsor":"Fujian Shengdi Pharmaceutical Co., Ltd.","startDate":"2026-02-25","conditions":"Severe Hypertriglyceridemia With a High Risk of Acute Pancreatitis","enrollment":108},{"nctId":"NCT06556277","phase":"NA","title":"Acute Consequences of Glucocorticoid Secretion in Overweight and Obese Individuals During Maximum Calorie Intake","status":"COMPLETED","sponsor":"Eleonora Seelig","startDate":"2024-09-01","conditions":"Glucocorticoids, Overweight and Obesity, Overeating","enrollment":23},{"nctId":"NCT00343460","phase":"PHASE3","title":"APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer","status":"COMPLETED","sponsor":"Heron Therapeutics","startDate":"2006-06","conditions":"Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific","enrollment":1428},{"nctId":"NCT07437586","phase":"PHASE2","title":"Topical GHK-Cu Gel for Acute Skin Wound Healing","status":"RECRUITING","sponsor":"Hudson Biotech","startDate":"2026-02-02","conditions":"Acute Standardized Cutaneous Wounds (Punch-biopsy Wounds)","enrollment":60},{"nctId":"NCT06578247","phase":"PHASE3","title":"Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML","status":"RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2024-11-19","conditions":"Leukemia","enrollment":700},{"nctId":"NCT07437547","phase":"PHASE2","title":"BPC 157 for Acute Hamstring Muscle Strain Repair","status":"RECRUITING","sponsor":"Hudson Biotech","startDate":"2026-02-02","conditions":"Hamstring Muscle Strain, Skeletal Muscle Injury","enrollment":120},{"nctId":"NCT06068478","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of Qingzhu Granules in the Treatment of Acute Gouty Arthritis","status":"COMPLETED","sponsor":"Tasly Pharmaceutical Group Co., Ltd","startDate":"2023-11-07","conditions":"Gouty Arthritis","enrollment":472},{"nctId":"NCT06592794","phase":"PHASE3","title":"A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2024-09-24","conditions":"Acute Gastroenteritis, Norovirus Acute Gastroenteritis","enrollment":37864},{"nctId":"NCT06603623","phase":"PHASE2","title":"Efficacy and Safety Trial of BHV-2100 for the Acute Treatment of Migraine","status":"COMPLETED","sponsor":"Biohaven Therapeutics Ltd.","startDate":"2024-10-10","conditions":"Migraine","enrollment":647},{"nctId":"NCT06587737","phase":"PHASE3","title":"Colchicine for the Reduction of Dependency and Vascular Events After an Acute Intracerebral Hemorrhage","status":"NOT_YET_RECRUITING","sponsor":"Population Health Research Institute","startDate":"2026-05-30","conditions":"Colchicine, ICH - Intracerebral Hemorrhage, Stroke","enrollment":1125},{"nctId":"NCT07430917","phase":"PHASE2","title":"Safety and Efficacy of J147 in Acute Ischemic Stroke","status":"NOT_YET_RECRUITING","sponsor":"Abrexa Pharmaceuticals, Inc.","startDate":"2026-03-20","conditions":"Acute Ischemic Stroke","enrollment":196},{"nctId":"NCT07431476","phase":"PHASE4","title":"Brimonidine 0.33% for Rosacea-Related Facial Erythema","status":"COMPLETED","sponsor":"Istanbul Training and Research Hospital","startDate":"2025-05-01","conditions":"Rosacea, Rosacea Subtype 1 (Erythematotelangiectatic)","enrollment":45},{"nctId":"NCT05354141","phase":"PHASE3","title":"Extracellular Vesicle Treatment for Acute Respiratory Distress Syndrome (ARDS) (EXTINGUISH ARDS)","status":"RECRUITING","sponsor":"Direct Biologics, LLC","startDate":"2022-07-01","conditions":"Acute Respiratory Distress Syndrome, ARDS","enrollment":970},{"nctId":"NCT06819592","phase":"PHASE3","title":"PRophylaxis Against Early VENTilator-associated Infections in Acute Brain Injury","status":"RECRUITING","sponsor":"The George Institute","startDate":"2025-10-30","conditions":"All-cause Mortality, Quality of Life, Disability, Intellectual","enrollment":3300},{"nctId":"NCT07392450","phase":"PHASE2","title":"A Study of TAK-755 in Adults With Acute Ischemic Stroke","status":"NOT_YET_RECRUITING","sponsor":"Takeda","startDate":"2026-04-15","conditions":"Acute Ischemic Stroke","enrollment":222},{"nctId":"NCT07413094","phase":"PHASE2","title":"Efficacy and Safety of YD0743 Treatment for Sepsis-Associated ARDS","status":"RECRUITING","sponsor":"Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.","startDate":"2026-02-02","conditions":"Sepsis","enrollment":309},{"nctId":"NCT06940141","phase":"PHASE2","title":"Rademikibart Add-on Treatment of an Acute Asthma Exacerbation (Seabreeze STAT Asthma)","status":"RECRUITING","sponsor":"Connect Biopharm LLC","startDate":"2025-08-08","conditions":"Asthma Acute","enrollment":160},{"nctId":"NCT06940154","phase":"PHASE2","title":"Rademikibart Add-on Treatment of an Acute COPD Exacerbation (Seabreeze STAT COPD)","status":"RECRUITING","sponsor":"Connect Biopharm LLC","startDate":"2025-08-12","conditions":"COPD Acute Exacerbation","enrollment":160},{"nctId":"NCT07286487","phase":"NA","title":"Glycyrrhetinic Acid and Acute Irritant Dermatitis","status":"NOT_YET_RECRUITING","sponsor":"University of Split, School of Medicine","startDate":"2026-03-01","conditions":"Irritant Contact Dermatitis","enrollment":30},{"nctId":"NCT05197426","phase":"PHASE2","title":"A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Japanese Participants With Acute Myeloid Leukemia (AML) in Complete Remission","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2022-01-17","conditions":"Acute Myeloid Leukemia","enrollment":19},{"nctId":"NCT04368559","phase":"PHASE3","title":"Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mundipharma Research Limited","startDate":"2020-05-11","conditions":"Candidemia, Mycoses, Fungal Infection","enrollment":602},{"nctId":"NCT06551181","phase":"PHASE3","title":"A Study on the Immune Response, Safety and the Occurrence of Respiratory Syncytial Virus (RSV)-Associated Respiratory Tract Illness After Administration of RSV OA Vaccine in Adults 60 Years and Older","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2024-08-05","conditions":"Respiratory Syncytial Virus Infections","enrollment":2621},{"nctId":"NCT06215859","phase":"PHASE3","title":"Study of MR-107A-02 for the Treatment of Acute Postoperative Pain Following Herniorrhaphy","status":"COMPLETED","sponsor":"Viatris Specialty LLC","startDate":"2023-12-29","conditions":"Acute Pain, Post Operative Pain, Pain","enrollment":579},{"nctId":"NCT07398612","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Human Adipose-Derived Stem Cell Exosomes in Acute Ischemic Stroke","status":"NOT_YET_RECRUITING","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2026-01-31","conditions":"Acute Ischemic Stroke","enrollment":60},{"nctId":"NCT04725110","phase":"PHASE2","title":"Direct Topical Lung T3 Treatment to Improve Outcome & Sequelae of COVID-19 Acute Respiratory Distress Syndrome","status":"WITHDRAWN","sponsor":"University of Minnesota","startDate":"2026-01-15","conditions":"Covid19, SARS-CoV Infection, ARDS","enrollment":""},{"nctId":"NCT07111468","phase":"PHASE3","title":"Clinical Trial to Evaluate the Efficacy and Safety of YHP2401 Compared to YHR2402 and YHR2403 for Acute Bronchitis","status":"COMPLETED","sponsor":"Yuhan Corporation","startDate":"2025-08-19","conditions":"Acute Bronchitis","enrollment":286},{"nctId":"NCT07396337","phase":"PHASE2","title":"Study to Assess the Efficacy and Safety of QHRD106 Injection in Acute Ischemic Stroke.","status":"RECRUITING","sponsor":"Changzhou Qianhong Bio-pharma Co., Ltd.","startDate":"2026-01-19","conditions":"Acute Ischemic Stroke","enrollment":320},{"nctId":"NCT05315726","phase":"NA","title":"The Effects of Muscle Vibration on the Development of Spasticity and Neuroplasticity in a Post-stroke Population","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2022-06-14","conditions":"Post-stroke Patient in Acute, Sub-acute Phase or Chronic","enrollment":165},{"nctId":"NCT06071767","phase":"PHASE1, PHASE2","title":"Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-04-01","conditions":"HIV-1-infection","enrollment":36},{"nctId":"NCT06880770","phase":"PHASE3","title":"Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis","status":"RECRUITING","sponsor":"Arrowhead Pharmaceuticals","startDate":"2025-04-24","conditions":"Severe Hypertriglyceridemia","enrollment":288},{"nctId":"NCT07215273","phase":"PHASE2","title":"Study of EL219 vs Standard of Care for Early Antifungal Therapy of Suspected Invasive Mould Infections","status":"RECRUITING","sponsor":"Elion Therapeutics, Inc.","startDate":"2026-02","conditions":"Suspected Invasive Mould Infection","enrollment":80},{"nctId":"NCT06809179","phase":"PHASE2","title":"A Clinical Trial to Assess the Efficacy, Safety, and Tolerability of a Repeat Dose of Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder","status":"RECRUITING","sponsor":"VistaGen Therapeutics, Inc.","startDate":"2025-01-09","conditions":"Social Anxiety Disorder","enrollment":60},{"nctId":"NCT06615557","phase":"PHASE3","title":"Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-4)","status":"RECRUITING","sponsor":"VistaGen Therapeutics, Inc.","startDate":"2024-09-16","conditions":"Social Anxiety Disorder (SAD)","enrollment":236},{"nctId":"NCT04624243","phase":"PHASE2","title":"Efficacy and Safety of MK-8189 in Participants With an Acute Episode of Schizophrenia (MK-8189-008)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-12-15","conditions":"Schizophrenia","enrollment":499},{"nctId":"NCT05953480","phase":"PHASE2","title":"A Phase 2b, Randomized, Double-blind Study of Redasemtide (S-005151) in Adult Participants With Acute Ischemic Stroke","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shionogi","startDate":"2023-07-14","conditions":"Acute Ischemic Stroke","enrollment":680},{"nctId":"NCT04716452","phase":"PHASE1","title":"Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relapsed/Refractory Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Keystone Nano, Inc","startDate":"2025-10-01","conditions":"Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia, Refractory, Refractory/Relapse Acute Myeloid Leukemia","enrollment":15},{"nctId":"NCT06564207","phase":"PHASE2","title":"Fostamatinib for Treating Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Adults","status":"NOT_YET_RECRUITING","sponsor":"Inova Health Care Services","startDate":"2026-08-30","conditions":"Acute Respiratory Distress Syndrome, ARDS","enrollment":40},{"nctId":"NCT07258771","phase":"PHASE4","title":"Upadacitinib Combined With Corticosteroids vs Corticosteroid Monotherapy Induction for Inpatients and Outpatients With Acute Severe Ulcerative Colitis","status":"RECRUITING","sponsor":"Berinstein, Jeffrey","startDate":"2026-01-16","conditions":"Ulcerative Colitis Acute","enrollment":110},{"nctId":"NCT05509868","phase":"PHASE3","title":"Study of PBK_L1704 for the Treatment of Moderate to Severe Acute Pain After Bunionectomy in South Korea","status":"COMPLETED","sponsor":"Pharmbio Korea Co., Ltd.","startDate":"2022-07-25","conditions":"Acute Pain","enrollment":182},{"nctId":"NCT07304518","phase":"PHASE2","title":"Phase II Trial of PRT-064040 Nasal Spray for the Treatment of Migraine in Adults","status":"RECRUITING","sponsor":"Sichuan Purity Pharmaceutical Technology Co., Ltd.","startDate":"2026-01-26","conditions":"Migraine","enrollment":456},{"nctId":"NCT05879432","phase":"PHASE2","title":"LSALT Peptide for Prevention or Attenuation of Acute Kidney Injury (AKI) in Patients Undergoing On-Pump Cardiac Surgery","status":"RECRUITING","sponsor":"Arch Biopartners Inc.","startDate":"2024-03-08","conditions":"Acute Kidney Injury, Cardiac Surgery","enrollment":240},{"nctId":"NCT07371624","phase":"PHASE1, PHASE2","title":"A Study of the Safety, Tolerability and Preliminary Efficacy of B2065 in Patients With Acute Ischemic Stroke.","status":"RECRUITING","sponsor":"Tasly Pharmaceutical Group Co., Ltd","startDate":"2025-12-31","conditions":"Acute Ischemic Stroke","enrollment":54},{"nctId":"NCT06404099","phase":"PHASE2","title":"RECOVER-SLEEP: Platform Protocol, Appendix_A (Hypersomnia)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Duke University","startDate":"2024-08-12","conditions":"Long COVID, Long COVID-19, Hypersomnia","enrollment":361},{"nctId":"NCT04091945","phase":"PHASE2","title":"A Study to Evaluate the Safety and Potential Efficacy of LT3001 Drug Product in Subjects With AIS","status":"COMPLETED","sponsor":"Lumosa Therapeutics Co., Ltd.","startDate":"2020-01-27","conditions":"Acute Ischemic Stroke","enrollment":24},{"nctId":"NCT07193901","phase":"PHASE2","title":"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Characteristics of (R)-Ketamine Hydrochloride Nasal Spray in Patients With Depression and Acute Suicidal Ideation or Behavior","status":"RECRUITING","sponsor":"Sichuan Purity Pharmaceutical Technology Co., Ltd.","startDate":"2025-05-27","conditions":"Major Depressive Disorder (MDD","enrollment":98},{"nctId":"NCT05737121","phase":"PHASE2","title":"Safety and Efficacy Study of VNX001 Compared to Its Individual Components (Lidocaine and Heparin) or Placebo in Subjects With IC/BPS","status":"RECRUITING","sponsor":"Vaneltix Pharma, Inc.","startDate":"2023-05-22","conditions":"Interstitial Cystitis, Bladder Pain Syndrome","enrollment":120},{"nctId":"NCT06404086","phase":"PHASE2","title":"RECOVER-SLEEP: Platform Protocol","status":"COMPLETED","sponsor":"Duke University","startDate":"2024-07-31","conditions":"Long COVID, Long COVID-19, Hypersomnia","enrollment":830},{"nctId":"NCT06143059","phase":"PHASE3","title":"The Effects of Sex Hormones and Alcohol on Sleep","status":"SUSPENDED","sponsor":"Lauren Whitehurst","startDate":"2024-01-08","conditions":"Alcohol Use Disorder","enrollment":130},{"nctId":"NCT07349771","phase":"PHASE2","title":"Axatilimab Plus Standard of Care Therapy for the Prevention of Graft Versus Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Cancer, ABRAXAS Trial","status":"NOT_YET_RECRUITING","sponsor":"Mayo Clinic","startDate":"2026-01-31","conditions":"Hematopoietic and Lymphatic System Neoplasm","enrollment":72},{"nctId":"NCT03470441","phase":"PHASE2","title":"A Study of Acute Myocardial Infarction Using FDY-5301","status":"COMPLETED","sponsor":"Faraday Pharmaceuticals, Inc.","startDate":"2017-10-27","conditions":"Acute Myocardial Infarction, STEMI","enrollment":120},{"nctId":"NCT05947955","phase":"PHASE2","title":"Rhu-pGSN for Acute Respiratory Distress Syndrome (ARDS)","status":"RECRUITING","sponsor":"BioAegis Therapeutics Inc.","startDate":"2024-10-03","conditions":"Acute Respiratory Distress Syndrome, Infections","enrollment":600}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1033,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Silicified microcrystalline cellulose"],"phase":"phase_3","status":"active","brandName":"Placebo (acute phase)","genericName":"Placebo (acute phase)","companyName":"ZS Pharma, Inc.","companyId":"zs-pharma-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Placebo is a small molecule intervention used in clinical trials for various conditions, including Influenza A, Hip Fractures, Acute Ischemic Stroke, Pneumonia, and Non-Infectious Anterior Uveitis. It is a control treatment used in studies, such as a Phase 2 randomized, double-blind, placebo-controlled trial for acute uncomplicated seasonal Influenza A in otherwise healthy adults.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}